ArticleJournal of patient-reported outcomes2017

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).

Joseph M Unger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.